GLUE

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) is a clinical-stage biotech company developing small-molecule drugs called molecular glue degraders that target disease-causing proteins for destruction. Its proprietary QuEEN™ platform combines AI, proteomics, and chemistry to design these precision therapies.

The company’s pipeline includes candidates for cancer and immune disorders, such as MRT-2359 for MYC-driven tumors and MRT-6160 targeting immune pathways. Monte Rosa recently signed a $5.7 billion licensing deal with Novartis, validating its technology and strengthening its position in the growing protein-degradation field.